Key points from article :
Terray Therapeutics, a biotechnology company revolutionizing drug discovery with scale experimentation and generative AI, has announced a strategic collaboration with Bristol Myers Squibb. This partnership focuses on discovering and developing small molecule therapeutics targeting specific disease areas, combining Terray’s advanced tNova platform with Bristol Myers Squibb’s expertise in development and commercialization.
Under the agreement, Terray will identify and refine small molecule compounds for targets nominated by Bristol Myers Squibb. Once the discovery phase is complete, Bristol Myers Squibb will oversee further development and commercialization. Terray will receive an upfront payment, along with milestone payments tied to preclinical, clinical, and sales achievements. Additionally, Terray will earn tiered royalties from the net sales of products resulting from this collaboration.
Jacob Berlin, Ph.D., CEO of Terray Therapeutics, expressed enthusiasm for the partnership, highlighting its potential to combine Terray’s precision and speed with Bristol Myers Squibb’s extensive capabilities. “This agreement underscores the value of our platform in addressing complex challenges in drug discovery,” he noted.
Terray’s tNova platform integrates generative AI with extensive chemical experimentation, creating precise, iterative datasets to optimize small molecules. This unique approach accelerates the discovery of effective drug candidates while addressing challenges in cost, speed, and success rates.
This collaboration signifies a significant step in advancing small molecule drug development, leveraging the strengths of both companies to address critical needs in healthcare.
